Cytokinetics, Incorporated $CYTK Stock Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the third quarter, Holdings Channel reports. The firm owned 1,576,135 shares of the biopharmaceutical company’s stock after selling 27,307 shares during the period. William Blair Investment Management LLC’s holdings in Cytokinetics were worth $103,883,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of CYTK. Physician Wealth Advisors Inc. boosted its holdings in Cytokinetics by 810.2% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 397 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Cytokinetics by 71.5% during the 3rd quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 191 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Cytokinetics during the second quarter valued at approximately $36,000. Manchester Capital Management LLC acquired a new position in shares of Cytokinetics during the third quarter valued at approximately $43,000. Finally, Allworth Financial LP lifted its position in shares of Cytokinetics by 35.6% in the third quarter. Allworth Financial LP now owns 732 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 192 shares in the last quarter.

Cytokinetics Price Performance

CYTK opened at $56.13 on Monday. The company’s 50 day simple moving average is $64.11 and its two-hundred day simple moving average is $69.78. Cytokinetics, Incorporated has a 1-year low of $53.55 and a 1-year high of $88.31. The firm has a market capitalization of $7.82 billion, a price-to-earnings ratio of -9.29 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The company had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. Cytokinetics’s revenue for the quarter was up 2356.5% on a year-over-year basis. During the same quarter last year, the company earned ($2.55) earnings per share. On average, equities analysts anticipate that Cytokinetics, Incorporated will post -5.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cytokinetics news, EVP Fady Malik sold 3,500 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $75.46, for a total value of $264,110.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company’s stock, valued at $11,613,444.92. This trade represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Blum sold 97,926 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $69.33, for a total value of $6,789,209.58. Following the completion of the sale, the chief executive officer directly owned 385,320 shares of the company’s stock, valued at $26,714,235.60. This trade represents a 20.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 178,426 shares of company stock worth $12,208,290. 2.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CYTK has been the topic of a number of research analyst reports. Needham & Company LLC lifted their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. UBS Group reissued a “buy” rating and issued a $104.00 price objective on shares of Cytokinetics in a research note on Wednesday, October 14th. William Blair initiated coverage on Cytokinetics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, Citizens Jmp upped their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.67.

Get Our Latest Stock Report on Cytokinetics

About Cytokinetics

(Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Further Reading

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report).

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.